var data={"title":"Unipolar depression in adults: Management of highly resistant (refractory) depression","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Unipolar depression in adults: Management of highly resistant (refractory) depression</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/contributors\" class=\"contributor contributor_credentials\">Michael Thase, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/contributors\" class=\"contributor contributor_credentials\">K Ryan Connolly, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/contributors\" class=\"contributor contributor_credentials\">Peter P Roy-Byrne, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/contributors\" class=\"contributor contributor_credentials\">David Solomon, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 18, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H6078004\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although numerous treatments are available for unipolar major depression (major depressive disorder), patients may be highly resistant (refractory) to many sequential treatment regimens, including multiple classes of antidepressants and adjunctive drugs, as well as electroconvulsive therapy and psychotherapy [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/1\" class=\"abstract_t\">1</a>]. </p><p>This topic reviews management and treatment of refractory depression. The epidemiology, assessment, prognosis, and treatment of resistant depression are discussed separately, as are the initial treatment of depression and clinical features and diagnosis of depression.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=unipolar-treatment-resistant-depression-in-adults-epidemiology-risk-factors-assessment-and-prognosis\" class=\"medical medical_review\">&quot;Unipolar treatment resistant depression in adults: Epidemiology, risk factors, assessment, and prognosis&quot;</a>.) &#160;</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=unipolar-depression-in-adults-treatment-of-resistant-depression\" class=\"medical medical_review\">&quot;Unipolar depression in adults: Treatment of resistant depression&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=unipolar-major-depression-in-adults-choosing-initial-treatment\" class=\"medical medical_review\">&quot;Unipolar major depression in adults: Choosing initial treatment&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=unipolar-depression-in-adults-assessment-and-diagnosis\" class=\"medical medical_review\">&quot;Unipolar depression in adults: Assessment and diagnosis&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H6077277\"><span class=\"h1\">DEFINITIONS</span></p><p class=\"headingAnchor\" id=\"H87698632\"><span class=\"h2\">Unipolar major depression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Unipolar major depression (major depressive disorder) is diagnosed in patients who have suffered at least one major depressive episode and have no history of mania (<a href=\"image.htm?imageKey=PSYCH%2F91106\" class=\"graphic graphic_table graphicRef91106 \">table 1</a>) or hypomania (<a href=\"image.htm?imageKey=PSYCH%2F91107\" class=\"graphic graphic_table graphicRef91107 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/2\" class=\"abstract_t\">2</a>]. A major depressive episode is a period lasting at least two weeks, with five or more of the following symptoms: depressed mood, anhedonia, insomnia or hypersomnia, change in appetite or weight, psychomotor retardation or agitation, low energy, poor concentration, thoughts of worthlessness or guilt, and recurrent thoughts about death or suicide (<a href=\"image.htm?imageKey=PSYCH%2F89994\" class=\"graphic graphic_table graphicRef89994 \">table 3</a>). Additional information about the clinical presentation and diagnosis of major depressive disorder is discussed separately. (See <a href=\"topic.htm?path=unipolar-depression-in-adults-assessment-and-diagnosis\" class=\"medical medical_review\">&quot;Unipolar depression in adults: Assessment and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H894657\"><span class=\"h2\">Treatment resistant depression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The term &ldquo;treatment resistant depression&rdquo; typically refers to major depressive episodes that do not respond satisfactorily after two trials of antidepressant monotherapy; however, the definition has not been standardized [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/3-5\" class=\"abstract_t\">3-5</a>]. The definition of treatment resistant depression is discussed separately. (See <a href=\"topic.htm?path=unipolar-treatment-resistant-depression-in-adults-epidemiology-risk-factors-assessment-and-prognosis#H6075260\" class=\"medical medical_review\">&quot;Unipolar treatment resistant depression in adults: Epidemiology, risk factors, assessment, and prognosis&quot;, section on 'Treatment resistant depression'</a>.)</p><p class=\"headingAnchor\" id=\"H87698680\"><span class=\"h2\">Treatment refractory depression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The term &ldquo;treatment refractory depression&rdquo; typically refers to unipolar major depressive episodes that are highly resistant to treatment and do not respond satisfactorily to many sequential treatment regimens. However, the definition has not been standardized, and there is no clear demarcation between treatment resistant depression (an episode that does not respond to one or two trials of antidepressant monotherapy) and treatment refractory depression. Our definition of treatment refractory depression is drawn in part from the inclusion criteria for studies of investigational treatments such as <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/6\" class=\"abstract_t\">6</a>], deep brain stimulation [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/1,7,8\" class=\"abstract_t\">1,7,8</a>], and ablative neurosurgery [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/9,10\" class=\"abstract_t\">9,10</a>]; the definition stipulates that patients are refractory to or refuse the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antidepressants &ndash; several (eg, three to six) trials with different drugs and classes &#160;</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adjunctive drugs &ndash; multiple (eg, two to four) trials with different drugs &#160;</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Electroconvulsive therapy (ECT) &ndash; at least one course </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adjunctive psychotherapy &ndash; at least one trial &#160;</p><p/><p class=\"headingAnchor\" id=\"H2556373\"><span class=\"h1\">MANAGEMENT</span></p><p class=\"headingAnchor\" id=\"H807206\"><span class=\"h2\">General approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For treatment refractory depression, we recommend referral to mental health clinicians, and suggest a conservative approach that includes ongoing pharmacotherapy and psychotherapy and avoids excessive investigations and treatments (eg, polypharmacy with four or more psychotropic medications). Repeated treatment failures may lead patients to feel helpless and demoralized; thus, management should include regular visits (eg, every two to eight weeks) to monitor safety and provide support [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/11\" class=\"abstract_t\">11</a>]. &#160;</p><p>Clinicians can encourage patients to function as best they can despite their refractory symptoms and to conceptualize their depression as a chronic disease, analogous to rheumatoid arthritis, diabetes mellitus, and chronic pain [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/11\" class=\"abstract_t\">11</a>]. Management includes interventions to help patients [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/11-14\" class=\"abstract_t\">11-14</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Learn about unipolar major depression.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adhere to ongoing treatment.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Learn healthy physical habits related to sleep and exercise. (See <a href=\"topic.htm?path=overview-of-insomnia-in-adults\" class=\"medical medical_review\">&quot;Overview of insomnia in adults&quot;</a> and <a href=\"topic.htm?path=the-benefits-and-risks-of-exercise\" class=\"medical medical_review\">&quot;The benefits and risks of exercise&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Learn healthy mental health habits related to coping with difficult situations and increasing self-awareness and social skills.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Focus upon psychosocial functioning and quality of life.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Find or rediscover meaning and a purpose in life.</p><p/><p>Clinicians should maintain hope for improvement but avoid setting unrealistic expectations, and try to help patients with treatment refractory depression accept ongoing symptoms without blaming themselves [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/11\" class=\"abstract_t\">11</a>]. A prospective, 48-week, observational study of a depression management program in 19 patients and their family members suggested that this approach may possibly improve depressive symptoms, psychosocial functioning, and quality of life [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/12\" class=\"abstract_t\">12</a>].</p><p class=\"headingAnchor\" id=\"H672133\"><span class=\"h2\">Setting</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In managing treatment refractory depression, the setting depends upon the severity; mild to moderate episodes are typically treated on an outpatient basis, and severe episodes on an inpatient basis. (See <a href=\"topic.htm?path=unipolar-depression-in-adults-treatment-of-resistant-depression\" class=\"medical medical_review\">&quot;Unipolar depression in adults: Treatment of resistant depression&quot;</a>.)</p><p>Specialized inpatient settings can be beneficial but their availability is limited, especially for extended hospitalizations. In a prospective observational study, 113 patients (approximately 70 percent with unipolar depression) were treated in a national-referral hospital unit dedicated to refractory, complex mood disorders [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/15\" class=\"abstract_t\">15</a>]. Prior to hospitalization for the current mood episode, patients had received on average 10 medications, and most had received electroconvulsive therapy (ECT). Multimodal treatment (including pharmacotherapy and psychotherapy, as well as assessment for neurosurgical interventions) was provided during a mean hospitalization of 23 weeks. At discharge, response (reduction of baseline symptoms &ge;50 percent) had occurred in 50 percent, with an average time to response of approximately 18 weeks; functional improvement occurred in 69 percent. &#160;</p><p class=\"headingAnchor\" id=\"H173033718\"><span class=\"h2\">Duration of an adequate trial</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We generally treat unipolar major depression for 6 to 12 weeks before deciding whether a regimen has sufficiently relieved symptoms [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/16-18\" class=\"abstract_t\">16-18</a>]. However, for patients who show little improvement (eg, reduction of baseline symptoms &le;25 percent) after 4 to 6 weeks, we administer next-step treatment [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/19\" class=\"abstract_t\">19</a>]. Additional information about the duration of an adequate treatment trial is discussed separately. &#160; </p><p class=\"headingAnchor\" id=\"H173033627\"><span class=\"h2\">Measurement based care</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Measurement based care is the systematic, quantitative assessment of symptoms that is typically performed at each visit [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/19\" class=\"abstract_t\">19</a>]. Psychosocial functioning, quality of life, medication adherence, and tolerability of treatment can also be measured.</p><p>The nine-item Patient Health Questionnaire is a self-report, standardized, rating scale that measures the severity of symptoms in patients with major depression, and is widely used to ascertain response to pharmacotherapy or psychotherapy (<a href=\"image.htm?imageKey=PC%2F59307\" class=\"graphic graphic_table graphicRef59307 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/20,21\" class=\"abstract_t\">20,21</a>]. Scores &gt;20 indicate severe depression, whereas scores &lt;5 indicate remission. A decrease &ge;50 percent indicates a significant clinical response. (See <a href=\"topic.htm?path=using-scales-to-monitor-symptoms-and-treat-depression-measurement-based-care#H100014092\" class=\"medical medical_review\">&quot;Using scales to monitor symptoms and treat depression (measurement based care)&quot;, section on 'Patient Health Questionnaire - Nine Item'</a>.)</p><p class=\"headingAnchor\" id=\"H2556503\"><span class=\"h1\">CHOOSING TREATMENT</span></p><p class=\"headingAnchor\" id=\"H807069\"><span class=\"h2\">Combination therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with treatment refractory depression, we suggest pharmacotherapy combined with psychotherapy, based upon randomized trials:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A meta-analysis of 16 trials compared combination treatment with pharmacotherapy alone in 1842 depressed patients (who were not selected for treatment resistant or treatment refractory depression) [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/22\" class=\"abstract_t\">22</a>]. Response occurred in more patients who received combination therapy (odds ratio 1.9, 95% CI 1.4-2.5). However, psychotherapy is often not available or is declined. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A subsequent one year randomized trial compared cognitive-behavioral therapy (CBT; 12 to 18 sessions) plus usual care (eg, pharmacotherapy) with usual care alone in 419 outpatients with treatment resistant depression [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/23\" class=\"abstract_t\">23</a>]. Remission occurred in more patients who received CBT plus usual care than usual care alone (28 versus 15 percent). </p><p/><p class=\"headingAnchor\" id=\"H6077291\"><span class=\"h3\">Pharmacotherapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with treatment refractory unipolar major depression frequently receive an antidepressant augmented with another drug, based upon the efficacy of augmentation in randomized trials of patients with treatment resistant depression. However, antidepressant monotherapy is a reasonable alternative. Many antidepressants and adjunctive drugs are available, and the choice begins with drugs that have not been previously used for the current depressive episode. Our general order of preference in choosing an antidepressant is as follows: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Selective serotonin reuptake inhibitor (see <a href=\"topic.htm?path=selective-serotonin-reuptake-inhibitors-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">&quot;Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serotonin-norepinephrine reuptake inhibitor (see <a href=\"topic.htm?path=serotonin-norepinephrine-reuptake-inhibitors-snris-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">&quot;Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Atypical antidepressant (see <a href=\"topic.htm?path=atypical-antidepressants-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">&quot;Atypical antidepressants: Pharmacology, administration, and side effects&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serotonin modulator (see <a href=\"topic.htm?path=serotonin-modulators-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">&quot;Serotonin modulators: Pharmacology, administration, and side effects&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tricyclic antidepressant (see <a href=\"topic.htm?path=tricyclic-and-tetracyclic-drugs-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">&quot;Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Monoamine oxidase inhibitor (see <a href=\"topic.htm?path=monoamine-oxidase-inhibitors-maois-for-treating-depressed-adults\" class=\"medical medical_review\">&quot;Monoamine oxidase inhibitors (MAOIs) for treating depressed adults&quot;</a>)</p><p/><p>While there is no evidence-based sequence for selecting augmentation agents, our general order of preference in choosing an adjunctive medication is as follows: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Second-generation antipsychotic</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">Lithium</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thyroid hormone</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Second antidepressant from a different class </p><p/><p>Second-generation antipsychotics have the best balance of efficacy and tolerability among these options, particularly in combination with modern, first-line antidepressants such as selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. Additional information about choosing treatment, the efficacy of different options, and the general principles that are used to administer treatment is discussed separately in the context of treatment resistant depression. (See <a href=\"topic.htm?path=unipolar-depression-in-adults-treatment-of-resistant-depression\" class=\"medical medical_review\">&quot;Unipolar depression in adults: Treatment of resistant depression&quot;</a>.) </p><p>Lack of response to numerous standard treatments may impel clinicians to prescribe many medications (&ge;4 psychotropic drugs). However, we generally avoid complex medication regimens because there are no data supporting their utility, and patients may feel worse due to the cumulative side effects. </p><p class=\"headingAnchor\" id=\"H96384166\"><span class=\"h3\">Adjunctive psychotherapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are multiple psychotherapies available for patients with treatment refractory depression, and the choice begins with available therapies that have not yet been administered. CBT has been studied most often in treatment resistant depression, and interpersonal psychotherapy has been widely studied for the initial treatment of depression. Other alternatives include psychodynamic psychotherapy, supportive psychotherapy, and family therapy. The efficacy and administration of these psychotherapies is discussed separately. (See <a href=\"topic.htm?path=overview-of-psychotherapies\" class=\"medical medical_review\">&quot;Overview of psychotherapies&quot;</a> and <a href=\"topic.htm?path=interpersonal-psychotherapy-ipt-for-depressed-adults-indications-theoretical-foundation-general-concepts-and-efficacy\" class=\"medical medical_review\">&quot;Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy&quot;</a> and <a href=\"topic.htm?path=unipolar-depression-in-adults-psychodynamic-psychotherapy\" class=\"medical medical_review\">&quot;Unipolar depression in adults: Psychodynamic psychotherapy&quot;</a> and <a href=\"topic.htm?path=unipolar-depression-in-adults-supportive-psychotherapy\" class=\"medical medical_review\">&quot;Unipolar depression in adults: Supportive psychotherapy&quot;</a> and <a href=\"topic.htm?path=family-and-couples-therapy-for-treating-depressed-adults\" class=\"medical medical_review\">&quot;Family and couples therapy for treating depressed adults&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H3619541417\"><span class=\"h2\">Transcranial magnetic stimulation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with mild to moderate depression may not respond satisfactorily to several courses of pharmacotherapy plus psychotherapy [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/24\" class=\"abstract_t\">24</a>]. For patients who are refractory to multiple (eg, one to three) next step antidepressant monotherapy trials and multiple (eg, two to four) adjunctive medication trials, as well as treatment with psychotherapy either alone or as augmentation, we suggest repetitive transcranial magnetic stimulation. Meta-analyses of randomized trials have found that for patients who have not responded to at least one antidepressant medication, repetitive transcranial magnetic stimulation is superior to sham treatment [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/25-35\" class=\"abstract_t\">25-35</a>]. In many studies, patients had failed multiple courses of pharmacotherapy and psychotherapy as well as a trial of electroconvulsive therapy (ECT) [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/28,31,36,37\" class=\"abstract_t\">28,31,36,37</a>]. Use of repetitive transcranial magnetic stimulation for treatment resistant depression is consistent with multiple practice guidelines [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/38-41\" class=\"abstract_t\">38-41</a>]. The efficacy, administration, safety, and adverse effects of transcranial magnetic stimulation for unipolar depression are discussed separately. (See <a href=\"topic.htm?path=unipolar-depression-in-adults-indications-efficacy-and-safety-of-transcranial-magnetic-stimulation-tms\" class=\"medical medical_review\">&quot;Unipolar depression in adults: Indications, efficacy, and safety of transcranial magnetic stimulation (TMS)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2892138456\"><span class=\"h2\">Treatments with potential benefit</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with treatment refractory depression may not respond to multiple sequential trials of different antidepressants and augmentation with other medications (eg, second-generation antipsychotics, <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, thyroid hormone, or a second antidepressant) <span class=\"nowrap\">and/or</span> psychotherapy, as well as a trial of ECT. These patients are candidates for augmentation with less established treatments, including botulinum toxin, <a href=\"topic.htm?path=celecoxib-drug-information\" class=\"drug drug_general\">celecoxib</a>, omega-3 fatty acids, S-adenosyl methionine, and <a href=\"topic.htm?path=pramipexole-drug-information\" class=\"drug drug_general\">pramipexole</a>. In addition, ECT may be beneficial.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Botulinum toxin </strong>&ndash; Randomized trials suggest that adjunctive botulinum toxin may benefit patients with unipolar major depression, but loss of blinding due to the drug&rsquo;s effect upon facial muscles is common [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/42,43\" class=\"abstract_t\">42,43</a>]. A pooled analysis of individual patient data from three randomized trials (total n = 134 patients), each lasting six weeks, compared <a href=\"topic.htm?path=onabotulinumtoxina-botox-drug-information\" class=\"drug drug_general\">onabotulinumtoxinA</a> (29 units for females or 40 units for males) with placebo [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/44\" class=\"abstract_t\">44</a>]. At baseline, antidepressants were prescribed to 64 percent of the patients; onabotulinumtoxinA and placebo were injected in a single session into the glabellar frown muscles of the forehead. Remission occurred in more patients who received active treatment than placebo (31 versus 7 percent), and adverse events for the two groups were comparable. However, the investigators acknowledged the difficulty of blinding patients and outcome raters. &#160; &#160; </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=celecoxib-drug-information\" class=\"drug drug_general\">Celecoxib</a> &ndash; Add-on treatment with celecoxib may be beneficial for treatment resistant unipolar major depression [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/45,46\" class=\"abstract_t\">45,46</a>]. A meta-analysis of four randomized trials lasting six or eight weeks compared celecoxib (200 to 400 mg per day) plus an antidepressant (generally a selective serotonin reuptake inhibitor) with placebo plus an antidepressant in 132 patients; remission occurred in more patients who received adjunctive celecoxib (odds ratio 8, 95% CI 3-21) [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/47\" class=\"abstract_t\">47</a>]. In the same study, another meta-analysis (10 randomized trials, 2750 patients with either major depression or depressive symptoms) compared celecoxib (used as monotherapy or as add-on treatment) with placebo, and found a significant, clinically small to moderate effect favoring celecoxib. However, heterogeneity across studies was high, as was risk of bias. Although adverse gastrointestinal or cardiovascular effects were comparable for celecoxib and placebo, the duration of treatment may have been too short for these adverse effects to manifest; several observational studies have found that treatment with selective serotonin reuptake inhibitors (SSRIs) plus nonsteroidal anti-inflammatory drugs is associated with bleeding [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/48\" class=\"abstract_t\">48</a>]. (See <a href=\"topic.htm?path=selective-serotonin-reuptake-inhibitors-pharmacology-administration-and-side-effects#H12543449\" class=\"medical medical_review\">&quot;Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects&quot;, section on 'Bleeding'</a>.) &#160;</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Exercise</strong> &ndash; Exercise as an add-on treatment may help patients who do not respond to pharmacotherapy. A 10-week randomized trial enrolled 42 patients with major depression who did not respond to at least six weeks of antidepressant treatment, and compared adjunctive aerobic exercise (two sessions per week, each lasting one hour, in a physical therapy setting) with a single consultation focused upon advice for physical activity [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/49\" class=\"abstract_t\">49</a>]. Improvement of both depression and cardiovascular fitness was greater with exercise. Another study found that even low dose exercise (eg, 20 minutes, three <span class=\"nowrap\">times/week</span> of moderate intensity exercise) may perhaps be beneficial [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/50\" class=\"abstract_t\">50</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">Lithium</a><strong> monotherapy</strong> &ndash; Older studies suggest that lithium monotherapy may effectively treat unipolar depression, but lithium is generally used as augmentation for treatment resistant patients. There is far less evidence for lithium monotherapy than for antidepressants [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/51-53\" class=\"abstract_t\">51-53</a>], and lithium can be difficult to use because of the risk of toxicity and need to monitor serum concentrations [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/54\" class=\"abstract_t\">54</a>]. (See <a href=\"topic.htm?path=unipolar-depression-in-adults-treatment-with-lithium\" class=\"medical medical_review\">&quot;Unipolar depression in adults: Treatment with lithium&quot;</a> and <a href=\"topic.htm?path=unipolar-depression-in-adults-treatment-of-resistant-depression#H3006621444\" class=\"medical medical_review\">&quot;Unipolar depression in adults: Treatment of resistant depression&quot;, section on 'Lithium'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=methylfolate-drug-information\" class=\"drug drug_general\">Methylfolate</a> &ndash; Methylfolate is the form of folate that crosses the blood brain barrier, and limited evidence suggests that adjunctive methylfolate may be effective for treatment refractory depression. In a 60-day randomized trial that compared L-methylfolate (15 mg per day) plus an SSRI with placebo plus an SSRI in 75 patients, response (reduction of baseline symptoms &ge;50 percent) occurred in more patients who received add-on L-methylfolate than placebo (32 versus 15 percent), and tolerability was comparable [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/55\" class=\"abstract_t\">55</a>]. However, remission was comparable with active drug and placebo (13 and 9 percent). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Omega-3 fatty acids</strong> &ndash; Multiple randomized trials suggest that augmentation of antidepressants with omega-3 fatty acids may benefit patients with treatment refractory depression:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>One meta-analysis of eight trials (n = 448 patients) compared adjunctive omega-3 fatty acids with placebo; the trials lasted 4 to 12 weeks and the dose of eicosapentaenoic acid was typically one gram per day [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/56\" class=\"abstract_t\">56</a>]. Improvement was greater with omega-3 fatty acids than placebo, and the clinical effect was moderate to large. Discontinuation of treatment due to adverse effects was less than 2 percent.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A second meta-analysis (13 trials) compared omega-3 fatty acids with placebo in 1233 patients diagnosed with unipolar major depression through standardized clinical interviews; approximately half of the patients were taking antidepressants [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/57\" class=\"abstract_t\">57</a>]. Improvement was greater with omega-3 fatty acids than placebo and the clinical effect was small to moderate. However, heterogeneity across studies was large; analyses of the heterogeneity found that higher doses of eicosapentaenoic acid (eg, 2 <span class=\"nowrap\">grams/day)</span> and concurrent treatment with antidepressants were each associated with better outcomes for omega-3 fatty acids.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A systematic review included a meta-analysis with 535 patients who were clinically diagnosed with depressive syndromes; the meta-analysis found that augmentation of antidepressants with eicosapentaenoic acid-predominant formulations of omega-3 fatty acids was superior to placebo, and the clinical effect was moderate to large (heterogeneity across studies was also moderate to large) [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/58\" class=\"abstract_t\">58</a>]. In addition, the review included a second meta-analysis which found a trend towards greater efficacy for augmentation with eicosapentaenoic acid-predominant formulations of omega-3 fatty acids, compared with monotherapy with eicosapentaenoic acid-predominant formulations of omega-3 fatty acids. &#160; </p><p/><p class=\"bulletIndent1\">Information about the use of omega-3 fatty acids for the initial treatment of unipolar depression, as well as the benefits, adverse effects, and safety of omega-3 fatty acids for cardiovascular health, is discussed separately. (See <a href=\"topic.htm?path=unipolar-depression-in-adults-and-initial-treatment-investigational-approaches#H84006745\" class=\"medical medical_review\">&quot;Unipolar depression in adults and initial treatment: Investigational approaches&quot;, section on 'Omega-3 fatty acids'</a> and <a href=\"topic.htm?path=fish-oil-and-marine-omega-3-fatty-acids\" class=\"medical medical_review\">&quot;Fish oil and marine omega-3 fatty acids&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">Quetiapine</a><strong> monotherapy</strong> &ndash; Quetiapine monotherapy may benefit patients with treatment refractory depression, but is typically used as an adjuvant with an antidepressant. Randomized trials compared quetiapine with placebo for episodes of nonpsychotic unipolar major depression that either had not been treated or had not responded satisfactorily to a single antidepressant trial; the trials excluded patients who did not respond to two or more antidepressants. Some advantages for quetiapine were observed in the trials. Additional information about the efficacy of quetiapine monotherapy is discussed separately, as are its adverse effects (<a href=\"image.htm?imageKey=PSYCH%2F82533\" class=\"graphic graphic_table graphicRef82533 \">table 5</a>). (See <a href=\"topic.htm?path=unipolar-depression-in-adults-treatment-with-second-generation-antipsychotics#H433345\" class=\"medical medical_review\">&quot;Unipolar depression in adults: Treatment with second-generation antipsychotics&quot;, section on 'Monotherapy for nonpsychotic depression'</a> and <a href=\"topic.htm?path=second-generation-antipsychotic-medications-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">&quot;Second-generation antipsychotic medications: Pharmacology, administration, and side effects&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>S-adenosyl methionine</strong> &ndash; S-adenosyl methionine (SAMe) is a metabolite of folate that facilitates the synthesis of neurotransmitters (including dopamine, norepinephrine, and serotonin), and may be effective and well tolerated as an adjunct for treatment refractory depression [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/56,59,60\" class=\"abstract_t\">56,59,60</a>]. A six-week randomized trial compared adjunctive SAMe (800 mg twice per day) with placebo in 73 patients with unipolar major depression who failed treatment with an SSRI, and found that remission occurred in more patients who received SAMe (36 versus 12 percent) [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/61\" class=\"abstract_t\">61</a>]. In addition, discontinuation of treatment because of adverse effects occurred in fewer patients who received augmentation with SAMe than placebo (5 versus 9 percent). Additional information about SAMe is available from the United States <a href=\"http://www.dsld.nlm.nih.gov/dsld/&amp;token=lCAcnbhqK15cHaTXfudtt1tN0Mb1kvPCCpEfqDjouhbQZsuo44h0GSJNSOwveti8&amp;TOPIC_ID=87500\" target=\"_blank\" class=\"external\">National Library of Medicine Dietary Supplement Database</a> and the <a href=\"https://nccih.nih.gov/health/supplements/SAMe&amp;token=xet4a8U02gaKYNXGdDyCV3nMSwsS1GDT6obUibXOA/cGvqS5uDupNllPE//82snzdKZLDEFzSio1SX1m9BkAoA==&amp;TOPIC_ID=87500\" target=\"_blank\" class=\"external\">National Library of Medicine monographs</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Stimulants and stimulant-like drugs</strong> &ndash; Augmenting antidepressants with stimulants (eg, <a href=\"topic.htm?path=lisdexamfetamine-drug-information\" class=\"drug drug_general\">lisdexamfetamine</a> or <a href=\"topic.htm?path=methylphenidate-drug-information\" class=\"drug drug_general\">methylphenidate</a>) or stimulant-like drugs (eg, <a href=\"topic.htm?path=modafinil-drug-information\" class=\"drug drug_general\">modafinil</a> or <a href=\"topic.htm?path=pramipexole-drug-information\" class=\"drug drug_general\">pramipexole</a>) may be helpful for some specific symptoms and patients. The use and efficacy of these options are discussed separately. (See <a href=\"topic.htm?path=unipolar-major-depression-in-adults-augmentation-of-antidepressants-with-stimulants-and-stimulant-like-drugs\" class=\"medical medical_review\">&quot;Unipolar major depression in adults: Augmentation of antidepressants with stimulants and stimulant-like drugs&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1159043950\"><span class=\"h2\">Treatments with little to no benefit</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Multiple randomized trials in patients with treatment resistant depression indicate that there is little to no benefit in augmenting an antidepressant with <a href=\"topic.htm?path=buspirone-drug-information\" class=\"drug drug_general\">buspirone</a>, folate, <a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">lamotrigine</a>, or <a href=\"topic.htm?path=pindolol-drug-information\" class=\"drug drug_general\">pindolol</a>.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=buspirone-drug-information\" class=\"drug drug_general\">Buspirone</a> &ndash; Two trials (n = 119 and 102) compared buspirone with placebo as augmentation in patients who did not respond to initial treatment of major depression with an SSRI; responses with adjunctive buspirone and placebo were comparable [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/62,63\" class=\"abstract_t\">62,63</a>]. In addition, a STAR*D trial found that symptomatic improvement and tolerability were inferior with adjunctive buspirone compared with adjunctive <a href=\"topic.htm?path=bupropion-drug-information\" class=\"drug drug_general\">bupropion</a> [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/54\" class=\"abstract_t\">54</a>]. (See <a href=\"topic.htm?path=unipolar-depression-in-adults-treatment-of-resistant-depression#H3737642162\" class=\"medical medical_review\">&quot;Unipolar depression in adults: Treatment of resistant depression&quot;, section on 'A second antidepressant'</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Folate</strong> &ndash; Randomized trials indicate that folate (<a href=\"topic.htm?path=folic-acid-drug-information\" class=\"drug drug_general\">folic acid</a>) is not useful for treatment refractory depression. A meta-analysis of four randomized trials compared add-on folic acid (0.5 to 10 mg per day) with placebo in patients currently unresponsive to antidepressants (n = 671); the benefit of adjunctive folic acid and placebo was comparable [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/56\" class=\"abstract_t\">56</a>]. In addition, other studies of folate have raised safety concerns, including masked B12 deficiency [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/60\" class=\"abstract_t\">60</a>]. </p><p/><p class=\"bulletIndent1\">Nevertheless, a small, prospective observational study identified 12 patients who had not responded to at least three medication trials and who manifested cerebral spinal fluid folate deficiency despite normal serum folate levels; treatment with add-on <a href=\"topic.htm?path=leucovorin-drug-information\" class=\"drug drug_general\">leucovorin</a> (also called folinic acid; 1 to 2 <span class=\"nowrap\">mg/kg</span> for at least six weeks) was associated with improvement in 10 patients [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/64\" class=\"abstract_t\">64</a>].</p><p/><p class=\"bulletIndent1\">Additional information about folate is available from the United States <a href=\"http://www.dsld.nlm.nih.gov/dsld/&amp;token=lCAcnbhqK15cHaTXfudtt1tN0Mb1kvPCCpEfqDjouhbQZsuo44h0GSJNSOwveti8&amp;TOPIC_ID=87500\" target=\"_blank\" class=\"external\">National Library of Medicine Dietary Supplements Database</a> and the <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/natural/1017.html&amp;token=PTSjFes3/QZNAGmgH8Pqb19MWTOoKMG5mZRbygb/AA+8TD3UTOFylSA2gFYumhub7p0QVd7myHUICtjJFkd+1YOp8TWi/+xxOjEXhZCmEQ0=&amp;TOPIC_ID=87500\" target=\"_blank\" class=\"external\">National Library of Medicine Monographs</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=lamotrigine-drug-information\" class=\"drug drug_general\">Lamotrigine</a> &ndash; Based upon two randomized, placebo controlled trials (n = 96 and 34), augmentation of antidepressants with lamotrigine for treatment resistant, unipolar major depression is not beneficial [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/65,66\" class=\"abstract_t\">65,66</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=metyrapone-drug-information\" class=\"drug drug_general\">Metyrapone</a> &ndash; The antiglucocorticoid metyrapone does not appear to help patients with treatment refractory depression. A five-week randomized trial in patients with treatment resistant depression (n = 143) found that improvement of depressive symptoms was comparable with add-on metyrapone (500 mg twice daily) and placebo [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/67\" class=\"abstract_t\">67</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=pindolol-drug-information\" class=\"drug drug_general\">Pindolol</a> &ndash; We do not augment antidepressants with pindolol for treatment resistant depression, based upon negative results in multiple randomized trials (n = 80, 38, 16, and 10) [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/68-71\" class=\"abstract_t\">68-71</a>], as well as a network meta-analysis [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/72\" class=\"abstract_t\">72</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Vagus nerve stimulation</strong> &ndash; We generally do <strong>not</strong> perform vagus nerve stimulation, which is a clinically available intervention that involves surgery to attach an electrode around one vagus nerve; the electrode is connected by a wire to a pulse generator implanted subcutaneously in the chest wall. There are no compelling data that indicate vagus nerve stimulation is efficacious for treatment refractory unipolar major depression [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/73,74\" class=\"abstract_t\">73,74</a>]. A 10-week trial enrolled 222 patients who did not respond to pharmacotherapy (two to six regimens) and randomly assigned them to vagus nerve stimulation or sham treatment; response (reduction of baseline symptoms &ge;50 percent) in the two groups was comparable (15 and 10 percent of patients) [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/75\" class=\"abstract_t\">75</a>]. Avoiding vagus nerve stimulation is consistent with multiple practice guidelines [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/39,40,76\" class=\"abstract_t\">39,40,76</a>]. Additional information about vagus nerve stimulation, including its efficacy, safety, and side effect profile, is discussed separately. (See <a href=\"topic.htm?path=unipolar-depression-in-adults-treatment-with-surgical-approaches#H9580637\" class=\"medical medical_review\">&quot;Unipolar depression in adults: Treatment with surgical approaches&quot;, section on 'Vagus nerve stimulation (VNS)'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H173030464\"><span class=\"h1\">INVESTIGATIONAL APPROACHES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Investigational therapies for refractory major depression include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">Ketamine</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Noninvasive neuromodulation therapies</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><span class=\"nowrap\">Invasive/surgical</span> neuromodulation therapies </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other potential therapies</p><p/><p>Patients with treatment refractory depression may be candidates for <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> and noninvasive neuromodulation interventions, whereas surgical interventions are reserved for patients with severe, intractable, and incapacitating major depression. </p><p class=\"headingAnchor\" id=\"H173030552\"><span class=\"h2\">Ketamine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The delayed therapeutic effect of many antidepressants may be due to their targeted action on the monoaminergic system, which is thought to be upstream from the central nervous system sites that are more directly involved in response to pharmacotherapy. A potentially more direct and immediate target is the glutamatergic system, including the N-methyl-D-aspartate (NMDA) receptor [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/77\" class=\"abstract_t\">77</a>]. </p><p><a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">Ketamine</a> is an NMDA receptor antagonist, and is a standard anesthetic drug that can transiently alleviate treatment refractory unipolar major depression. Most studies have administered the drug intravenously, using subanesthetic doses; other less studied routes of giving the drug include intramuscular, intranasal, oral, and sublingual administration [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/78-80\" class=\"abstract_t\">78-80</a>].</p><p>Although off-label use of <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> for depression has increased, we suggest that clinicians limit the use of ketamine to research settings [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/81\" class=\"abstract_t\">81</a>]. The demonstrated benefit of ketamine is only short lived, the drug is associated with bladder toxicity and is potentially neurotoxic, and ketamine is liable to <span class=\"nowrap\">abuse/diversion</span> [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/82-86\" class=\"abstract_t\">82-86</a>]. Nor is it established whether ketamine is a bona fide antidepressant or merely a transient <span class=\"nowrap\">intoxicant/euphoriant</span> [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/83\" class=\"abstract_t\">83</a>]. A cautious approach to the use of ketamine is consistent with recommendations from the American Psychiatric Association [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/82\" class=\"abstract_t\">82</a>]. </p><p>For patients who receive <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> outside of a research setting, we suggest that clinicians regularly monitor the patient&rsquo;s psychiatric status [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/84\" class=\"abstract_t\">84</a>]; as an example, interviewing acutely ill patients at least once per week and stable patients receiving maintenance treatment with ketamine at least once per month. At a minimum, clinicians should ask about depression, <span class=\"nowrap\">dissociation/psychosis,</span> and misuse of the drug. &#160;</p><p>The efficacy of <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> for treatment refractory depression rests upon randomized trials, which indicate that a single infusion of ketamine produces a rapid response (eg, within 40 to 120 minutes) in at least 50 percent of patients; however, the effect dissipates by day 10 to 14 [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/87-89\" class=\"abstract_t\">87-89</a>]. As an example:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One systematic review of seven trials compared <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> with a control condition (placebo or active medication) in 172 patients with unipolar or bipolar major depression [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/82\" class=\"abstract_t\">82</a>]. A single dose of ketamine (0.5 <span class=\"nowrap\">mg/kg)</span> or the control was administered intravenously (six trials) or intranasally (one trial); most patients received no concomitant therapy. Response (reduction of baseline symptoms &ge;50 percent) at multiple posttreatment time points occurred in more patients who received ketamine than the control condition:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Two hours &ndash; 51 versus 2 percent of patients</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>One day &ndash; 53 versus 7 percent</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Seven days &ndash; 31 versus 7 percent</p><p/><p class=\"bulletIndent1\">By day 14, response was present in only 11 percent of the patients who received <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A meta-analysis of nine trials compared intravenous <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> (0.5 <span class=\"nowrap\">mg/kg</span> infused over 40 minutes) with a control condition (typically placebo) in patients with unipolar depression (n = 208) or bipolar depression (n = 26); study drugs were typically administered as add-on therapy [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/90\" class=\"abstract_t\">90</a>]. Response was more likely to occur in patients who received ketamine than controls, starting at 40 minutes and persisting at multiple subsequent time points; at day 7, response was three times more likely with ketamine (relative risk 3, 95% CI 2-7). &#160; </p><p/><p>There are no well-established clinical predictors or biomarkers of acute response to <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/91\" class=\"abstract_t\">91</a>].</p><p>Sustained improvement of depression may occur with repeated infusions of <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/83,92\" class=\"abstract_t\">83,92</a>]. One trial randomly assigned patients with treatment resistant depression (n = 67) to one of four treatments: ketamine two times per week, placebo two times per week, ketamine three times per week, or placebo three times per week [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/93\" class=\"abstract_t\">93</a>]. The dose of ketamine was 0.5 <span class=\"nowrap\">mg/kg,</span> all study drugs were infused intravenously over 40 minutes, and current antidepressant drugs were continued. Response at day 15 occurred in more patients who received twice weekly ketamine than placebo (69 versus 15 percent), and more often with thrice weekly ketamine than placebo (54 versus 6 percent of patients). The improvement that occurred with ketamine persisted during subsequent treatment with open-label ketamine for two weeks.</p><p>The long-term benefits of <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> are not known, due to the short duration of treatment and lack of follow-up in most studies [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/94\" class=\"abstract_t\">94</a>]. A case series of three outpatients found variable responses during a 12-month course of treatment that included 16 to 34 total infusions per patient [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/95\" class=\"abstract_t\">95</a>]. In addition, concerns about the long-term adverse effects of ketamine include cognitive impairment [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/96\" class=\"abstract_t\">96</a>].</p><p>Transient adverse effects of <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> in randomized trials included significant, clinically large dissociative and psychotomimetic effects at 40 to 60 minutes post infusion, which subsequently resolved within four hours [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/82,83,87,90\" class=\"abstract_t\">82,83,87,90</a>]. In addition, hemodynamic effects included time-limited tachycardia and increases in blood pressure. Two trials observed mean increases in systolic blood pressure of 8 and 19 mm Hg within 40 minutes of infusion, which normalized 4 hours after infusion [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/82\" class=\"abstract_t\">82</a>]. Other common adverse effects included blurred vision, dizziness, and nausea or vomiting [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/97\" class=\"abstract_t\">97</a>]. The intensity of dissociation induced by ketamine appears to diminish with repeated infusions [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/93\" class=\"abstract_t\">93</a>].</p><p>Augmentation with <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> may accelerate response to antidepressant treatment, which often takes 6 to 12 weeks [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/97\" class=\"abstract_t\">97</a>]. A four-week randomized trial compared a single infusion of add-on ketamine (0.5 <span class=\"nowrap\">mg/kg)</span> with placebo on day 1 of newly initiated treatment with <a href=\"topic.htm?path=escitalopram-drug-information\" class=\"drug drug_general\">escitalopram</a> 10 <span class=\"nowrap\">mg/day</span> [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/98\" class=\"abstract_t\">98</a>]. The sample consisted of 27 patients with unipolar major depression, approximately half of whom were classified as treatment resistant. Study drugs were administered after a two week washout of prior pharmacotherapy. Response occurred in more patients treated with adjunctive ketamine than placebo (92 versus 57 percent), and the mean time to response was shorter with ketamine plus escitalopram than placebo plus escitalopram (6 versus 27 days). In addition, more than half of the patients responded within two hours of receiving intravenous ketamine, compared with none of the patients who received placebo. None of the patients discontinued treatment due to adverse effects.</p><p>In addition, one randomized trial (n = 18) suggests that onset of antidepressant effect may be faster with <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> than electroconvulsive therapy [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/99\" class=\"abstract_t\">99</a>], and a prospective observational study found that ketamine led to a moderately large reduction of depressive symptoms in patients (n = 17) who had previously not responded to electroconvulsive therapy (ECT) [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/6\" class=\"abstract_t\">6</a>]. However, ketamine is not an alternative to ECT [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/82\" class=\"abstract_t\">82</a>].</p><p>Studies of <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> for depression have typically occurred in hospital settings in collaboration with anesthesiologists [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/96,100,101\" class=\"abstract_t\">96,100,101</a>]; however, outpatient clinics offering treatment are available [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/83\" class=\"abstract_t\">83</a>]. </p><p class=\"headingAnchor\" id=\"H696208463\"><span class=\"h3\">Suicidal ideation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Randomized trials suggest that <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> may be useful for short-term treatment of suicidal ideation. A meta-analysis of patient level data from eight randomized trials compared a single intravenous infusion of ketamine (0.5 <span class=\"nowrap\">mg/kg)</span> with a control condition (either saline or <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a>) in 167 patients with active or passive suicidal ideation at study entry [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/102\" class=\"abstract_t\">102</a>]. Most of the patients were diagnosed with unipolar major depression (77 percent); other diagnoses included bipolar disorder and posttraumatic stress disorder. Approximately 50 percent of patients were concurrently treated with psychotropic medications. After adjusting for potential confounds (eg, age, diagnosis, and use of pharmacotherapy) and concurrent changes in other depressive symptoms, greater improvement with ketamine began within one day of treatment, and resolution of suicidal ideation by day seven occurred in more patients who received ketamine than controls (60 versus 32 percent). </p><p>Additional information about management of suicidal ideation is discussed separately. (See <a href=\"topic.htm?path=suicidal-ideation-and-behavior-in-adults#H19\" class=\"medical medical_review\">&quot;Suicidal ideation and behavior in adults&quot;, section on 'Management'</a>.)</p><p class=\"headingAnchor\" id=\"H1705059349\"><span class=\"h3\">Esketamine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">Ketamine</a> is a racemic mixture of two stereoisomers that are mirror images of each other and thus not identical in that they cannot be superimposed upon each other (similar to one&rsquo;s hands). One of the stereoisomers, S-ketamine (esketamine), binds more potently to the NMDA receptor than the other stereoisomer [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/103\" class=\"abstract_t\">103</a>].</p><p>The clinical benefit of esketamine appears to be comparable to that of <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> (see <a href=\"#H173030552\" class=\"local\">'Ketamine'</a> above): </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One trial randomly assigned patients with treatment resistant depression (n = 30) to receive intravenous infusions of esketamine 0.2 <span class=\"nowrap\">mg/kg,</span> esketamine 0.4 <span class=\"nowrap\">mg/kg,</span> or placebo. Double-blind treatment occurred during the first week, with infusions on day 1 and day 4, followed by an open-label treatment phase with up to four infusions of esketamine over two weeks, and a subsequent follow-up assessment-only phase for another two weeks [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/103\" class=\"abstract_t\">103</a>]. Following the first dose of study drug, response (reduction of baseline symptoms &gt;50 percent) occurred in more patients treated with esketamine 0.2 <span class=\"nowrap\">mg/kg</span> or esketamine 0.4 <span class=\"nowrap\">mg/kg</span> than placebo (67 and 64 versus 0 percent). The benefit of active treatment persisted for the entire five weeks of the study. The most common adverse effects of esketamine were dissociation, headache, and nausea; in two cases, esketamine 0.4 <span class=\"nowrap\">mg/kg</span> caused severe dissociation that resolved within four hours.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A subsequent one-week randomized trial compared intranasal esketamine (28, 56, or 84 mg twice weekly) with placebo as an adjunct to oral antidepressant in 67 patients with treatment resistant depression [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/104\" class=\"abstract_t\">104</a>]. Improvement of depression was greater with each dose of esketamine than placebo, the antidepressant effect began within two hours of the first dose, and larger doses of esketamine provided a greater benefit than smaller doses. The benefit of active treatment persisted during subsequent treatment (total treatment = 74 days), as well as eight weeks of post-treatment follow-up. The most common adverse effects of esketamine were dizziness, headache, dissociation, and nausea. In addition, most patients treated with esketamine experienced elevations in <span class=\"nowrap\">systolic/diastolic</span> blood pressure within 40 minutes of administering the drug, with a maximum mean change of <span class=\"nowrap\">19/10</span> mm Hg. The elevated values typically returned to baseline within two hours.</p><p/><p class=\"headingAnchor\" id=\"H2322383228\"><span class=\"h2\">Other potential therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other investigational treatments that potentially may help patients with refractory unipolar major depression include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Basimglurant</strong> &ndash; Basimglurant is a glutamatergic antagonist akin to <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a> (see <a href=\"#H173030552\" class=\"local\">'Ketamine'</a> above) and may perhaps be useful for treatment refractory depression [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/105\" class=\"abstract_t\">105</a>]. One trial enrolled patients (n = 332) with treatment resistant depression and ongoing antidepressant treatment, and randomly assigned them to six weeks of adjunctive basimglurant 0.5 <span class=\"nowrap\">mg/day,</span> basimglurant 1.5 <span class=\"nowrap\">mg/day,</span> or placebo [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/106\" class=\"abstract_t\">106</a>]. Assessments by clinicians found that improvement with each dose of add-on basimglurant and placebo was comparable. However, patient self-report assessments indicated that remission occurred in more patients who received basimglurant 1.5 <span class=\"nowrap\">mg/day</span> than placebo (36 versus 22 percent). Discontinuation of treatment due to adverse events was comparable across the three groups (approximately 5 to 7 percent of patients).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=buprenorphine-drug-information\" class=\"drug drug_general\">Buprenorphine</a><strong> plus samidorphan</strong> &ndash; Adjunctive treatment with the combination of buprenorphine and samidorphan, which both act upon opioid receptors, may possibly be useful for treatment refractory depression [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/107\" class=\"abstract_t\">107</a>]. Patients who did not respond to an antidepressant (n = 135) were randomly assigned to four weeks of add-on treatment with buprenorphine (2 mg) plus samidorphan (2 mg), buprenorphine (8 mg) plus samidorphan (8 mg), or placebo [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/108\" class=\"abstract_t\">108</a>]. Nonresponders to add-on placebo were then randomly assigned to one of the three adjunctive treatments for another four weeks. Across the two stages of the entire study, improvement was greater with <span class=\"nowrap\">buprenorphine/samidorphan</span> (2 <span class=\"nowrap\">mg/2</span> mg) than placebo, and stopping treatment with <span class=\"nowrap\">buprenorphine/samidorphan</span> did not lead to opioid withdrawal. However, discontinuation of treatment due to adverse effects was 12 times greater with <span class=\"nowrap\">buprenorphine/samidorphan</span> than placebo (19.3 versus 1.6 percent of patients); relatively common adverse effects with <span class=\"nowrap\">buprenorphine/samidorphan</span> included dizziness, dysgeusia, headache, nausea, sedation, and vomiting.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Meditation</strong> &ndash; Meditation is an investigational add-on treatment that might benefit patients with treatment refractory depression [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/109\" class=\"abstract_t\">109</a>]. An eight-week, open-label randomized trial compared adjunctive meditation with a wait list control condition in patients (n = 25) with unipolar major depression that did not respond to at least eight weeks of antidepressant treatment [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/110\" class=\"abstract_t\">110</a>]. The meditation intervention was a group program that included breathing exercises, yoga postures, and sitting meditation; the program required 3.5 <span class=\"nowrap\">hours/day</span> for the first week and 2 <span class=\"nowrap\">hours/day</span> for the remaining seven weeks. Improvement of depression was greater with adjunctive meditation, compared with the control condition, and the active treatment was well tolerated.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=nitrous-oxide-drug-information\" class=\"drug drug_general\">Nitrous oxide</a> &ndash; Nitrous oxide is an NMDA receptor antagonist and a standard anesthetic drug that may perhaps help patients with treatment refractory depression. A randomized trial compared adjunctive inspiratory nitrous oxide (50 percent nitrous oxide plus 50 percent oxygen) with placebo (50 percent nitrogen plus 50 percent oxygen) in patients who met criteria for treatment resistant depression at baseline and were receiving a stable treatment regimen (n = 20) [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/111\" class=\"abstract_t\">111</a>]. Study drugs were administered in a single session lasting one hour. Improvement of depression was greater with add-on nitrous oxide than placebo at two hours, 24 hours, and one week posttreatment. However, nitrous oxide may be abused because of its intoxicating properties. Antagonism of the NMDA receptor also occurs with <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a>, which is another investigational approach to managing highly resistant depression. (See <a href=\"#H173030552\" class=\"local\">'Ketamine'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Rapastinel</strong> &ndash; The investigational drug rapastinel acts as an NMDA agonist and may have rapid antidepressant effects [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/107\" class=\"abstract_t\">107</a>]. A randomized trial compared a single intravenous dose of rapastinel (5 or 10 <span class=\"nowrap\">mg/kg)</span> with placebo in 70 patients with unipolar major depression who did not respond to antidepressants [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/112,113\" class=\"abstract_t\">112,113</a>]. Posttreatment assessments on day 1, 3, and 7 found that improvement was greater with each dose of rapastinel than placebo, and the clinical effect for each dose was approximately moderate. Assessments at day 14 indicated that the benefit of active drug had dissipated. Dizziness occurred more often with rapastinel than placebo.</p><p/><p class=\"headingAnchor\" id=\"H6077305\"><span class=\"h2\">Noninvasive neuromodulation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Noninvasive neuromodulation procedures use an electric current or magnetic field to stimulate the central nervous system [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/38\" class=\"abstract_t\">38</a>]. Clinically available procedures for patients with treatment resistant depression include ECT and repetitive transcranial magnetic stimulation (TMS). ECT and TMS are discussed separately, including their efficacy and tolerability. (See <a href=\"topic.htm?path=overview-of-electroconvulsive-therapy-ect-for-adults\" class=\"medical medical_review\">&quot;Overview of electroconvulsive therapy (ECT) for adults&quot;</a> and <a href=\"topic.htm?path=unipolar-depression-in-adults-indications-efficacy-and-safety-of-transcranial-magnetic-stimulation-tms\" class=\"medical medical_review\">&quot;Unipolar depression in adults: Indications, efficacy, and safety of transcranial magnetic stimulation (TMS)&quot;</a> and <a href=\"topic.htm?path=unipolar-major-depression-in-adults-indications-for-and-efficacy-of-electroconvulsive-therapy-ect#H21629511\" class=\"medical medical_review\">&quot;Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)&quot;, section on 'Compared with transcranial magnetic stimulation'</a>.)</p><p>For patients with unipolar major depression who are refractory to numerous sequential regimens of standard treatments, including pharmacotherapy, psychotherapy, ECT, and repetitive TMS, several noninvasive neuromodulation procedures are under investigation in research settings at tertiary referral centers; these include magnetic seizure therapy, focal electrically administered seizure therapy, transcranial direct current stimulation, transcranial low voltage pulsed electromagnetic fields stimulation, trigeminal nerve stimulation, and low field magnetic stimulation. In addition, cranial electrical stimulation is a clinically available, noninvasive approach. The efficacy, safety, and side effects of experimental noninvasive neuromodulation procedures are discussed separately. (See <a href=\"topic.htm?path=depression-in-adults-overview-of-neuromodulation-procedures#H29061923\" class=\"medical medical_review\">&quot;Depression in adults: Overview of neuromodulation procedures&quot;, section on 'Noninvasive neuromodulation therapies'</a>.) </p><p class=\"headingAnchor\" id=\"H14367098\"><span class=\"h2\">Invasive/surgical neuromodulation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with severe, intractable, and disabling unipolar major depression, which does not respond to numerous (eg, 7 to 10) trials of standard therapies and has persisted for years (eg, &ge;2 to 5), may be candidates for investigational neurosurgical interventions that lack high quality efficacy data [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/1,114\" class=\"abstract_t\">1,114</a>]. The most widely studied surgical intervention is deep brain stimulation; however, one randomized trial found that deep brain stimulation was not beneficial for refractory depression [<a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/115\" class=\"abstract_t\">115</a>]. Less common invasive approaches include direct cortical stimulation and ablative neurosurgery. Invasive treatments should be pursued only at tertiary referral centers that are conducting research and providing rigorous oversight to ensure that the procedure is indicated. The efficacy, safety, and side effects of experimental <span class=\"nowrap\">invasive/surgical</span> neuromodulation procedures are discussed separately. (See <a href=\"topic.htm?path=unipolar-depression-in-adults-treatment-with-surgical-approaches\" class=\"medical medical_review\">&quot;Unipolar depression in adults: Treatment with surgical approaches&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=depression-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Depression (The Basics)&quot;</a> and <a href=\"topic.htm?path=when-you-have-depression-and-another-health-problem-the-basics\" class=\"medical medical_basics\">&quot;Patient education: When you have depression and another health problem (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=depression-in-adults-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Depression in adults (Beyond the Basics)&quot;</a> and <a href=\"topic.htm?path=depression-treatment-options-for-adults-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Depression treatment options for adults (Beyond the Basics)&quot;</a> and <a href=\"topic.htm?path=electroconvulsive-therapy-ect-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Electroconvulsive therapy (ECT) (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H14367195\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Unipolar major depression (major depressive disorder) is diagnosed in patients who have suffered at least one major depressive episode (<a href=\"image.htm?imageKey=PSYCH%2F89994\" class=\"graphic graphic_table graphicRef89994 \">table 3</a>) and have no history of mania (<a href=\"image.htm?imageKey=PSYCH%2F91106\" class=\"graphic graphic_table graphicRef91106 \">table 1</a>) or hypomania (<a href=\"image.htm?imageKey=PSYCH%2F91107\" class=\"graphic graphic_table graphicRef91107 \">table 2</a>). (See <a href=\"topic.htm?path=unipolar-depression-in-adults-assessment-and-diagnosis\" class=\"medical medical_review\">&quot;Unipolar depression in adults: Assessment and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment resistant depression typically refers to a major depressive episode that does not respond satisfactorily after two trials of antidepressant monotherapy; however, the definition has not been standardized. (See <a href=\"topic.htm?path=unipolar-treatment-resistant-depression-in-adults-epidemiology-risk-factors-assessment-and-prognosis#H6075260\" class=\"medical medical_review\">&quot;Unipolar treatment resistant depression in adults: Epidemiology, risk factors, assessment, and prognosis&quot;, section on 'Treatment resistant depression'</a> and <a href=\"topic.htm?path=unipolar-depression-in-adults-treatment-of-resistant-depression\" class=\"medical medical_review\">&quot;Unipolar depression in adults: Treatment of resistant depression&quot;</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment refractory depression typically refers to unipolar major depressive episodes that do not respond satisfactorily to many sequential standard regimens, including multiple antidepressants and adjunctive drugs, as well as at least one trial each of electroconvulsive therapy, repetitive transcranial magnetic stimulation, and adjunctive psychotherapy. However, the definition has not been standardized, and there is no clear demarcation between treatment resistant and treatment refractory depression. (See <a href=\"#H87698680\" class=\"local\">'Treatment refractory depression'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For treatment refractory depression, we suggest a conservative approach that avoids excessive investigations and treatments, rather than administering aggressive, complicated regimens (eg, polypharmacy with four or more psychotropic drugs) (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Regular visits should be scheduled to monitor safety and provide support. While administering pharmacotherapy and psychotherapy, clinicians can help patients manage their illness as a chronic disease by learning about unipolar major depression, adhering to ongoing treatment, learning healthy physical habits related to sleep and exercise, learning healthy mental health habits related to coping with difficult situations and increasing social skills, and focusing upon psychosocial functioning. (See <a href=\"#H807206\" class=\"local\">'General approach'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For treatment refractory depression, we suggest pharmacotherapy plus psychotherapy, rather than pharmacotherapy alone (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). However, pharmacotherapy alone is a reasonable alternative. (See <a href=\"#H807069\" class=\"local\">'Combination therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with treatment refractory depression frequently receive an antidepressant augmented with another drug; however, antidepressant monotherapy is a reasonable alternative. The choice begins with drugs that have not yet been administered. Our general order of preference in choosing an antidepressant is as follows: selective serotonin reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor, atypical antidepressant, serotonin modulator, tricyclic, and monoamine oxidase inhibitor. Our general order of preference in choosing an adjunctive medication is as follows: second-generation antipsychotic, <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, thyroid hormone, and a second antidepressant from a different class. (See <a href=\"#H6077291\" class=\"local\">'Pharmacotherapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In selecting psychotherapy for treatment refractory depression, the choice begins with available therapies that have not yet been administered. We prefer either cognitive-behavioral therapy or interpersonal psychotherapy. Other reasonable alternatives include psychodynamic psychotherapy, supportive psychotherapy, and family therapy. (See <a href=\"#H96384166\" class=\"local\">'Adjunctive psychotherapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with treatment refractory depression, we suggest not performing vagus nerve stimulation (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H1159043950\" class=\"local\">'Treatments with little to no benefit'</a> above and <a href=\"topic.htm?path=unipolar-depression-in-adults-treatment-with-surgical-approaches#H9580637\" class=\"medical medical_review\">&quot;Unipolar depression in adults: Treatment with surgical approaches&quot;, section on 'Vagus nerve stimulation (VNS)'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with treatment refractory depression may be candidates for the anesthetic <a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">ketamine</a>, preferably administered in clinical trials investigating the drug. Treatment with ketamine that occurs outside of a research setting should include regular monitoring of the patient&rsquo;s psychiatric status; as an example, interviewing acutely ill patients at least once per week and stable patients receiving maintenance treatment with ketamine at least once per month. At a minimum, clinicians should ask about depression, <span class=\"nowrap\">dissociation/psychosis,</span> and misuse of the drug. (See <a href=\"#H173030552\" class=\"local\">'Ketamine'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other investigational approaches include basimglurant, <a href=\"topic.htm?path=buprenorphine-drug-information\" class=\"drug drug_general\">buprenorphine</a> and samidorphan, meditation, <a href=\"topic.htm?path=nitrous-oxide-drug-information\" class=\"drug drug_general\">nitrous oxide</a>, and rapastinel. In addition, clinical trials are investigating noninvasive neuromodulation interventions that include magnetic seizure therapy, focal electrically administered seizure therapy, transcranial direct current stimulation, and transcranial low voltage pulsed electromagnetic fields stimulation, trigeminal nerve stimulation, and low field magnetic stimulation. Cranial electrical stimulation is a clinically available, noninvasive neuromodulation intervention. (See <a href=\"#H2322383228\" class=\"local\">'Other potential therapies'</a> above and <a href=\"#H6077305\" class=\"local\">'Noninvasive neuromodulation'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with severe, intractable, and disabling unipolar major depression may be candidates for clinical trials investigating neurosurgical interventions, including deep brain stimulation and direct cortical stimulation. Although ablative neurosurgery is clinically available, this is a rarely used, last resort treatment. (See <a href=\"#H14367098\" class=\"local\">'Invasive/surgical neuromodulation'</a> above and <a href=\"topic.htm?path=unipolar-depression-in-adults-treatment-with-surgical-approaches\" class=\"medical medical_review\">&quot;Unipolar depression in adults: Treatment with surgical approaches&quot;</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/1\" class=\"nounderline abstract_t\">Malone DA Jr, Dougherty DD, Rezai AR, et al. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry 2009; 65:267.</a></li><li class=\"breakAll\">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/3\" class=\"nounderline abstract_t\">Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry 2005; 66 Suppl 8:5.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/4\" class=\"nounderline abstract_t\">Rush AJ, Warden D, Wisniewski SR, et al. STAR*D: revising conventional wisdom. CNS Drugs 2009; 23:627.</a></li><li class=\"breakAll\">Gaynes BN, Lux LJ, Lloyd SW, et al. Nonpharmacologic Interventions for Treatment-Resistant Depression in Adults, Comparative Effectiveness Review No. 33. United States Agency for Healthcare Research and Quality. Report Number 11-EHC056-EF. Rockville, MD September, 2011.</li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/6\" class=\"nounderline abstract_t\">Ibrahim L, Diazgranados N, Luckenbaugh DA, et al. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:1155.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/7\" class=\"nounderline abstract_t\">Lozano AM, Mayberg HS, Giacobbe P, et al. Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry 2008; 64:461.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/8\" class=\"nounderline abstract_t\">Bewernick BH, Hurlemann R, Matusch A, et al. Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatry 2010; 67:110.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/9\" class=\"nounderline abstract_t\">Christmas D, Eljamel MS, Butler S, et al. Long term outcome of thermal anterior capsulotomy for chronic, treatment refractory depression. J Neurol Neurosurg Psychiatry 2011; 82:594.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/10\" class=\"nounderline abstract_t\">Shields DC, Asaad W, Eskandar EN, et al. Prospective assessment of stereotactic ablative surgery for intractable major depression. Biol Psychiatry 2008; 64:449.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/11\" class=\"nounderline abstract_t\">Keitner GI, Mansfield AK. Management of treatment-resistant depression. Psychiatr Clin North Am 2012; 35:249.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/12\" class=\"nounderline abstract_t\">Ryan CE, Keitner GI, Bishop S. An adjunctive Management of Depression Program for difficult-to-treat depressed patients and their families. Depress Anxiety 2010; 27:27.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/13\" class=\"nounderline abstract_t\">Goldberg RW, Dickerson F, Lucksted A, et al. Living well: an intervention to improve self-management of medical illness for individuals with serious mental illness. Psychiatr Serv 2013; 64:51.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/14\" class=\"nounderline abstract_t\">Swan J, Sorrell E, MacVicar B, et al. &quot;Coping with depression&quot;: an open study of the efficacy of a group psychoeducational intervention in chronic, treatment-refractory depression. J Affect Disord 2004; 82:125.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/15\" class=\"nounderline abstract_t\">Wooderson SC, Juruena MF, Fekadu A, et al. Prospective evaluation of specialist inpatient treatment for refractory affective disorders. J Affect Disord 2011; 131:92.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/16\" class=\"nounderline abstract_t\">Rush AJ. STAR*D: what have we learned? Am J Psychiatry 2007; 164:201.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/17\" class=\"nounderline abstract_t\">Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 2009; 70 Suppl 6:16.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/18\" class=\"nounderline abstract_t\">Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 53:649.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/19\" class=\"nounderline abstract_t\">McIntyre RS. When should you move beyond first-line therapy for depression? J Clin Psychiatry 2010; 71 Suppl 1:16.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/20\" class=\"nounderline abstract_t\">Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999; 282:1737.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/21\" class=\"nounderline abstract_t\">Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/22\" class=\"nounderline abstract_t\">Pampallona S, Bollini P, Tibaldi G, et al. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry 2004; 61:714.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/23\" class=\"nounderline abstract_t\">Wiles N, Thomas L, Abel A, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet 2013; 381:375.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/24\" class=\"nounderline abstract_t\">Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/25\" class=\"nounderline abstract_t\">Holtzheimer PE 3rd, Russo J, Avery DH. A meta-analysis of repetitive transcranial magnetic stimulation in the treatment of depression. Psychopharmacol Bull 2001; 35:149.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/26\" class=\"nounderline abstract_t\">Kozel FA, George MS. Meta-analysis of left prefrontal repetitive transcranial magnetic stimulation (rTMS) to treat depression. J Psychiatr Pract 2002; 8:270.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/27\" class=\"nounderline abstract_t\">Schutter DJ. Quantitative review of the efficacy of slow-frequency magnetic brain stimulation in major depressive disorder. Psychol Med 2010; 40:1789.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/28\" class=\"nounderline abstract_t\">Schutter DJ. Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis. Psychol Med 2009; 39:65.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/29\" class=\"nounderline abstract_t\">Burt T, Lisanby SH, Sackeim HA. Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. Int J Neuropsychopharmacol 2002; 5:73.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/30\" class=\"nounderline abstract_t\">Slotema CW, Blom JD, Hoek HW, Sommer IE. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry 2010; 71:873.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/31\" class=\"nounderline abstract_t\">Lam RW, Chan P, Wilkins-Ho M, Yatham LN. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and metaanalysis. Can J Psychiatry 2008; 53:621.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/32\" class=\"nounderline abstract_t\">Allan CL, Herrmann LL, Ebmeier KP. Transcranial magnetic stimulation in the management of mood disorders. Neuropsychobiology 2011; 64:163.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/33\" class=\"nounderline abstract_t\">Herrmann LL, Ebmeier KP. Factors modifying the efficacy of transcranial magnetic stimulation in the treatment of depression: a review. J Clin Psychiatry 2006; 67:1870.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/34\" class=\"nounderline abstract_t\">McNamara B, Ray JL, Arthurs OJ, Boniface S. Transcranial magnetic stimulation for depression and other psychiatric disorders. Psychol Med 2001; 31:1141.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/35\" class=\"nounderline abstract_t\">Gaynes BN, Lloyd SW, Lux L, et al. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. J Clin Psychiatry 2014; 75:477.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/36\" class=\"nounderline abstract_t\">Avery DH, Isenberg KE, Sampson SM, et al. Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. J Clin Psychiatry 2008; 69:441.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/37\" class=\"nounderline abstract_t\">Connolly KR, Helmer A, Cristancho MA, et al. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center. J Clin Psychiatry 2012; 73:e567.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/38\" class=\"nounderline abstract_t\">Kennedy SH, Milev R, Giacobbe P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies. J Affect Disord 2009; 117 Suppl 1:S44.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/39\" class=\"nounderline abstract_t\">American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition. Am J Psychiatry 2010; 167 (supplement):1.</a></li><li class=\"breakAll\">American Psychiatric Association:Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition, 2010. http://psychiatryonline.org/guidelines.aspx (Accessed on April 17, 2012).</li><li class=\"breakAll\">Trangle M, Dieperink B, Gabert T, et al. Institute for Clinical Systems Improvement. Major Depression in Adults in Primary Care. Updated May 2012. http://www.icsi.org/depression_5/depression__major__in_adults_in_primary_care_3.html (Accessed on December 12, 2012).</li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/42\" class=\"nounderline abstract_t\">Finzi E, Rosenthal NE. Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial. J Psychiatr Res 2014; 52:1.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/43\" class=\"nounderline abstract_t\">Wollmer MA, de Boer C, Kalak N, et al. Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res 2012; 46:574.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/44\" class=\"nounderline abstract_t\">Magid M, Finzi E, Kruger TH, et al. Treating depression with botulinum toxin: a pooled analysis of randomized controlled trials. Pharmacopsychiatry 2015; 48:205.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/45\" class=\"nounderline abstract_t\">Na KS, Lee KJ, Lee JS, et al. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2014; 48:79.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/46\" class=\"nounderline abstract_t\">Faridhosseini F, Sadeghi R, Farid L, Pourgholami M. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol 2014; 29:216.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/47\" class=\"nounderline abstract_t\">K&ouml;hler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014; 71:1381.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/48\" class=\"nounderline abstract_t\">Anglin R, Moayyedi P, Leontiadis GI. Anti-inflammatory Intervention in Depression. JAMA Psychiatry 2015; 72:512.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/49\" class=\"nounderline abstract_t\">Danielsson L, Papoulias I, Petersson EL, et al. Exercise or basic body awareness therapy as add-on treatment for major depression: a controlled study. J Affect Disord 2014; 168:98.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/50\" class=\"nounderline abstract_t\">Greer TL, Trombello JM, Rethorst CD, et al. IMPROVEMENTS IN PSYCHOSOCIAL FUNCTIONING AND HEALTH-RELATED QUALITY OF LIFE FOLLOWING EXERCISE AUGMENTATION IN PATIENTS WITH TREATMENT RESPONSE BUT NONREMITTED MAJOR DEPRESSIVE DISORDER: RESULTS FROM THE TREAD STUDY. Depress Anxiety 2016; 33:870.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/51\" class=\"nounderline abstract_t\">Khan MC, Wickham EA, Reed JV. Lithium versus placebo in acute depression: a clinical trial. Int Clin Psychopharmacol 1987; 2:47.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/52\" class=\"nounderline abstract_t\">Souza FG, Goodwin GM. Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. Br J Psychiatry 1991; 158:666.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/53\" class=\"nounderline abstract_t\">Linder J, Fyr&ouml; B, Pettersson U, Werner S. Acute antidepressant effect of lithium is associated with fluctuation of calcium and magnesium in plasma. A double-blind study on the antidepressant effect of lithium and clomipramine. Acta Psychiatr Scand 1989; 80:27.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/54\" class=\"nounderline abstract_t\">Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354:1243.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/55\" class=\"nounderline abstract_t\">Papakostas GI, Shelton RC, Zajecka JM, et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry 2012; 169:1267.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/56\" class=\"nounderline abstract_t\">Sarris J, Murphy J, Mischoulon D, et al. Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. Am J Psychiatry 2016; 173:575.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/57\" class=\"nounderline abstract_t\">Mocking RJ, Harmsen I, Assies J, et al. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry 2016; 6:e756.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/58\" class=\"nounderline abstract_t\">Hallahan B, Ryan T, Hibbeln JR, et al. Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. Br J Psychiatry 2016; 209:192.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/59\" class=\"nounderline abstract_t\">Nelson JC. S-adenosyl methionine (SAMe) augmentation in major depressive disorder. Am J Psychiatry 2010; 167:889.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/60\" class=\"nounderline abstract_t\">Nelson JC. The evolving story of folate in depression and the therapeutic potential of l-methylfolate. Am J Psychiatry 2012; 169:1223.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/61\" class=\"nounderline abstract_t\">Papakostas GI, Mischoulon D, Shyu I, et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry 2010; 167:942.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/62\" class=\"nounderline abstract_t\">Land&eacute;n M, Bj&ouml;rling G, Agren H, Fahl&eacute;n T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998; 59:664.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/63\" class=\"nounderline abstract_t\">Appelberg BG, Syv&auml;lahti EK, Koskinen TE, et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001; 62:448.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/64\" class=\"nounderline abstract_t\">Pan LA, Martin P, Zimmer T, et al. Neurometabolic Disorders: Potentially Treatable Abnormalities in Patients With Treatment-Refractory Depression and Suicidal Behavior. Am J Psychiatry 2017; 174:42.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/65\" class=\"nounderline abstract_t\">Santos MA, Rocha FL, Hara C. Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. Prim Care Companion J Clin Psychiatry 2008; 10:187.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/66\" class=\"nounderline abstract_t\">Barbee JG, Thompson TR, Jamhour NJ, et al. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry 2011; 72:1405.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/67\" class=\"nounderline abstract_t\">McAllister-Williams RH, Anderson IM, Finkelmeyer A, et al. Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial. Lancet Psychiatry 2016; 3:117.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/68\" class=\"nounderline abstract_t\">Perry EB, Berman RM, Sanacora G, et al. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. J Clin Psychiatry 2004; 65:238.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/69\" class=\"nounderline abstract_t\">P&eacute;rez V, Soler J, Puigdemont D, et al. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch Gen Psychiatry 1999; 56:375.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/70\" class=\"nounderline abstract_t\">Moreno FA, Gelenberg AJ, Bachar K, Delgado PL. Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry 1997; 58:437.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/71\" class=\"nounderline abstract_t\">Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 1996; 41:201.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/72\" class=\"nounderline abstract_t\">Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry 2015; 76:e487.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/73\" class=\"nounderline abstract_t\">Shuchman M. Approving the vagus-nerve stimulator for depression. N Engl J Med 2007; 356:1604.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/74\" class=\"nounderline abstract_t\">Daban C, Martinez-Aran A, Cruz N, Vieta E. Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review. J Affect Disord 2008; 110:1.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/75\" class=\"nounderline abstract_t\">Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005; 58:347.</a></li><li class=\"breakAll\">National Institute for Health and Clinical Excellence (NICE). Vagus nerve stimulation for treatment-resistant depression, IPG330. December, 2009 http://www.nice.org.uk/ (Accessed on December 30, 2012).</li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/77\" class=\"nounderline abstract_t\">Bond DJ, Lim KO. 13C magnetic resonance spectroscopy and glutamate metabolism in mood disorders: Current challenges, potential opportunities. Am J Psychiatry 2014; 171:1240.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/78\" class=\"nounderline abstract_t\">Galvez V, O'Keefe E, Cotiga L, et al. Long-lasting effects of a single subcutaneous dose of ketamine for treating melancholic depression: a case report. Biol Psychiatry 2013.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/79\" class=\"nounderline abstract_t\">Lapidus KA, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 2014; 76:970.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/80\" class=\"nounderline abstract_t\">Schoevers RA, Chaves TV, Balukova SM, et al. Oral ketamine for the treatment of pain and treatment-resistant depression&dagger;. Br J Psychiatry 2016; 208:108.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/81\" class=\"nounderline abstract_t\">Kellner CH, Greenberg RM, Ahle GM, Liebman LS. Electroconvulsive therapy is a standard treatment; ketamine is not (yet). Am J Psychiatry 2014; 171:796.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/82\" class=\"nounderline abstract_t\">Newport DJ, Carpenter LL, McDonald WM, et al. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Am J Psychiatry 2015; 172:950.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/83\" class=\"nounderline abstract_t\">Malhi GS, Byrow Y, Cassidy F, et al. Ketamine: stimulating antidepressant treatment? BJPsych Open 2016; 2:e5.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/84\" class=\"nounderline abstract_t\">Schak KM, Vande Voort JL, Johnson EK, et al. Potential Risks of Poorly Monitored Ketamine Use in Depression Treatment. Am J Psychiatry 2016; 173:215.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/85\" class=\"nounderline abstract_t\">Baker SC, Shabir S, Georgopoulos NT, Southgate J. Ketamine-Induced Apoptosis in Normal Human Urothelial Cells: A Direct, N-Methyl-d-Aspartate Receptor-Independent Pathway Characterized by Mitochondrial Stress. Am J Pathol 2016; 186:1267.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/86\" class=\"nounderline abstract_t\">Jhang JF, Birder LA, Chancellor MB, Kuo HC. Patient characteristics for different therapeutic strategies in the management ketamine cystitis. Neurourol Urodyn 2017; 36:687.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/87\" class=\"nounderline abstract_t\">Fond G, Loundou A, Rabu C, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl) 2014; 231:3663.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/88\" class=\"nounderline abstract_t\">McGirr A, Berlim MT, Bond DJ, et al. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 2015; 45:693.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/89\" class=\"nounderline abstract_t\">Caddy C, Amit BH, McCloud TL, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev 2015; :CD011612.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/90\" class=\"nounderline abstract_t\">Kishimoto T, Chawla JM, Hagi K, et al. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med 2016; 46:1459.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/91\" class=\"nounderline abstract_t\">Monteggia LM, Zarate C Jr. Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr Opin Neurobiol 2015; 30:139.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/92\" class=\"nounderline abstract_t\">Vande Voort JL, Morgan RJ, Kung S, et al. Continuation phase intravenous ketamine in adults with treatment-resistant depression. J Affect Disord 2016; 206:300.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/93\" class=\"nounderline abstract_t\">Singh JB, Fedgchin M, Daly EJ, et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. Am J Psychiatry 2016; 173:816.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/94\" class=\"nounderline abstract_t\">Schatzberg AF. A word to the wise about ketamine. Am J Psychiatry 2014; 171:262.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/95\" class=\"nounderline abstract_t\">Szymkowicz SM, Finnegan N, Dale RM. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. J Affect Disord 2013; 147:416.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/96\" class=\"nounderline abstract_t\">Mathews DC, Zarate CA Jr. Current status of ketamine and related compounds for depression. J Clin Psychiatry 2013; 74:516.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/97\" class=\"nounderline abstract_t\">Schwartz J, Murrough JW, Iosifescu DV. Ketamine for treatment-resistant depression: recent developments and clinical applications. Evid Based Ment Health 2016; 19:35.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/98\" class=\"nounderline abstract_t\">Hu YD, Xiang YT, Fang JX, et al. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med 2016; 46:623.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/99\" class=\"nounderline abstract_t\">Ghasemi M, Kazemi MH, Yoosefi A, et al. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res 2014; 215:355.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/100\" class=\"nounderline abstract_t\">Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiatry 2012; 72:537.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/101\" class=\"nounderline abstract_t\">Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013; 170:1134.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/102\" class=\"nounderline abstract_t\">Wilkinson ST, Ballard ED, Bloch MH, et al. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry 2018; 175:150.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/103\" class=\"nounderline abstract_t\">Singh JB, Fedgchin M, Daly E, et al. Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study. Biol Psychiatry 2016; 80:424.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/104\" class=\"nounderline abstract_t\">Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry 2018; 75:139.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/105\" class=\"nounderline abstract_t\">Lindemann L, Porter RH, Scharf SH, et al. Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression. J Pharmacol Exp Ther 2015; 353:213.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/106\" class=\"nounderline abstract_t\">Quiroz JA, Tamburri P, Deptula D, et al. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial. JAMA Psychiatry 2016; 73:675.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/107\" class=\"nounderline abstract_t\">Machado-Vieira R, Henter ID, Zarate CA Jr. New targets for rapid antidepressant action. Prog Neurobiol 2017; 152:21.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/108\" class=\"nounderline abstract_t\">Fava M, Memisoglu A, Thase ME, et al. Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial. Am J Psychiatry 2016; 173:499.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/109\" class=\"nounderline abstract_t\">Janakiramaiah N, Gangadhar BN, Naga Venkatesha Murthy PJ, et al. Antidepressant efficacy of Sudarshan Kriya Yoga (SKY) in melancholia: a randomized comparison with electroconvulsive therapy (ECT) and imipramine. J Affect Disord 2000; 57:255.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/110\" class=\"nounderline abstract_t\">Sharma A, Barrett MS, Cucchiara AJ, et al. A Breathing-Based Meditation Intervention for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Randomized Pilot Study. J Clin Psychiatry 2017; 78:e59.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/111\" class=\"nounderline abstract_t\">Nagele P, Duma A, Kopec M, et al. Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial. Biol Psychiatry 2015; 78:10.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/112\" class=\"nounderline abstract_t\">Moskal JR, Burch R, Burgdorf JS, et al. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs 2014; 23:243.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/113\" class=\"nounderline abstract_t\">Preskorn S, Macaluso M, Mehra DO, et al. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract 2015; 21:140.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/114\" class=\"nounderline abstract_t\">Shelton RC, Osuntokun O, Heinloth AN, Corya SA. Therapeutic options for treatment-resistant depression. CNS Drugs 2010; 24:131.</a></li><li><a href=\"https://www.uptodate.com/contents/unipolar-depression-in-adults-management-of-highly-resistant-refractory-depression/abstract/115\" class=\"nounderline abstract_t\">Dougherty DD, Rezai AR, Carpenter LL, et al. A Randomized Sham-Controlled Trial of Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Chronic Treatment-Resistant Depression. Biol Psychiatry 2015; 78:240.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 87500 Version 27.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H14367195\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H6078004\" id=\"outline-link-H6078004\">INTRODUCTION</a></li><li><a href=\"#H6077277\" id=\"outline-link-H6077277\">DEFINITIONS</a><ul><li><a href=\"#H87698632\" id=\"outline-link-H87698632\">Unipolar major depression</a></li><li><a href=\"#H894657\" id=\"outline-link-H894657\">Treatment resistant depression</a></li><li><a href=\"#H87698680\" id=\"outline-link-H87698680\">Treatment refractory depression</a></li></ul></li><li><a href=\"#H2556373\" id=\"outline-link-H2556373\">MANAGEMENT</a><ul><li><a href=\"#H807206\" id=\"outline-link-H807206\">General approach</a></li><li><a href=\"#H672133\" id=\"outline-link-H672133\">Setting</a></li><li><a href=\"#H173033718\" id=\"outline-link-H173033718\">Duration of an adequate trial</a></li><li><a href=\"#H173033627\" id=\"outline-link-H173033627\">Measurement based care</a></li></ul></li><li><a href=\"#H2556503\" id=\"outline-link-H2556503\">CHOOSING TREATMENT</a><ul><li><a href=\"#H807069\" id=\"outline-link-H807069\">Combination therapy</a><ul><li><a href=\"#H6077291\" id=\"outline-link-H6077291\">- Pharmacotherapy</a></li><li><a href=\"#H96384166\" id=\"outline-link-H96384166\">- Adjunctive psychotherapy</a></li></ul></li><li><a href=\"#H3619541417\" id=\"outline-link-H3619541417\">Transcranial magnetic stimulation</a></li><li><a href=\"#H2892138456\" id=\"outline-link-H2892138456\">Treatments with potential benefit</a></li><li><a href=\"#H1159043950\" id=\"outline-link-H1159043950\">Treatments with little to no benefit</a></li></ul></li><li><a href=\"#H173030464\" id=\"outline-link-H173030464\">INVESTIGATIONAL APPROACHES</a><ul><li><a href=\"#H173030552\" id=\"outline-link-H173030552\">Ketamine</a><ul><li><a href=\"#H696208463\" id=\"outline-link-H696208463\">- Suicidal ideation</a></li><li><a href=\"#H1705059349\" id=\"outline-link-H1705059349\">- Esketamine</a></li></ul></li><li><a href=\"#H2322383228\" id=\"outline-link-H2322383228\">Other potential therapies</a></li><li><a href=\"#H6077305\" id=\"outline-link-H6077305\">Noninvasive neuromodulation</a></li><li><a href=\"#H14367098\" id=\"outline-link-H14367098\">Invasive/surgical neuromodulation</a></li></ul></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H6077881\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H14367195\" id=\"outline-link-H14367195\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PSYCH/87500|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PSYCH/91106\" class=\"graphic graphic_table\">- DSM-5 diagnostic criteria for manic episode</a></li><li><a href=\"image.htm?imageKey=PSYCH/91107\" class=\"graphic graphic_table\">- DSM-5 diagnostic criteria for hypomanic episode</a></li><li><a href=\"image.htm?imageKey=PSYCH/89994\" class=\"graphic graphic_table\">- DSM-5 criteria for a major depressive episode</a></li><li><a href=\"image.htm?imageKey=PC/59307\" class=\"graphic graphic_table\">- PHQ-9 questionnaire</a></li><li><a href=\"image.htm?imageKey=PSYCH/82533\" class=\"graphic graphic_table\">- Adverse effects of antipsychotic meds</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=atypical-antidepressants-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">Atypical antidepressants: Pharmacology, administration, and side effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=depression-in-adults-overview-of-neuromodulation-procedures\" class=\"medical medical_review\">Depression in adults: Overview of neuromodulation procedures</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=family-and-couples-therapy-for-treating-depressed-adults\" class=\"medical medical_review\">Family and couples therapy for treating depressed adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fish-oil-and-marine-omega-3-fatty-acids\" class=\"medical medical_review\">Fish oil and marine omega-3 fatty acids</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=interpersonal-psychotherapy-ipt-for-depressed-adults-indications-theoretical-foundation-general-concepts-and-efficacy\" class=\"medical medical_review\">Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=monoamine-oxidase-inhibitors-maois-for-treating-depressed-adults\" class=\"medical medical_review\">Monoamine oxidase inhibitors (MAOIs) for treating depressed adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-electroconvulsive-therapy-ect-for-adults\" class=\"medical medical_review\">Overview of electroconvulsive therapy (ECT) for adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-insomnia-in-adults\" class=\"medical medical_review\">Overview of insomnia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-psychotherapies\" class=\"medical medical_review\">Overview of psychotherapies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=depression-the-basics\" class=\"medical medical_basics\">Patient education: Depression (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=depression-in-adults-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Depression in adults (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=depression-treatment-options-for-adults-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Depression treatment options for adults (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=electroconvulsive-therapy-ect-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Electroconvulsive therapy (ECT) (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=when-you-have-depression-and-another-health-problem-the-basics\" class=\"medical medical_basics\">Patient education: When you have depression and another health problem (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=second-generation-antipsychotic-medications-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">Second-generation antipsychotic medications: Pharmacology, administration, and side effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=selective-serotonin-reuptake-inhibitors-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=serotonin-modulators-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">Serotonin modulators: Pharmacology, administration, and side effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=serotonin-norepinephrine-reuptake-inhibitors-snris-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=suicidal-ideation-and-behavior-in-adults\" class=\"medical medical_review\">Suicidal ideation and behavior in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-benefits-and-risks-of-exercise\" class=\"medical medical_review\">The benefits and risks of exercise</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tricyclic-and-tetracyclic-drugs-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=unipolar-depression-in-adults-and-initial-treatment-investigational-approaches\" class=\"medical medical_review\">Unipolar depression in adults and initial treatment: Investigational approaches</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=unipolar-depression-in-adults-assessment-and-diagnosis\" class=\"medical medical_review\">Unipolar depression in adults: Assessment and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=unipolar-depression-in-adults-indications-efficacy-and-safety-of-transcranial-magnetic-stimulation-tms\" class=\"medical medical_review\">Unipolar depression in adults: Indications, efficacy, and safety of transcranial magnetic stimulation (TMS)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=unipolar-depression-in-adults-psychodynamic-psychotherapy\" class=\"medical medical_review\">Unipolar depression in adults: Psychodynamic psychotherapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=unipolar-depression-in-adults-supportive-psychotherapy\" class=\"medical medical_review\">Unipolar depression in adults: Supportive psychotherapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=unipolar-depression-in-adults-treatment-of-resistant-depression\" class=\"medical medical_review\">Unipolar depression in adults: Treatment of resistant depression</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=unipolar-depression-in-adults-treatment-with-lithium\" class=\"medical medical_review\">Unipolar depression in adults: Treatment with lithium</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=unipolar-depression-in-adults-treatment-with-second-generation-antipsychotics\" class=\"medical medical_review\">Unipolar depression in adults: Treatment with second-generation antipsychotics</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=unipolar-depression-in-adults-treatment-with-surgical-approaches\" class=\"medical medical_review\">Unipolar depression in adults: Treatment with surgical approaches</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=unipolar-major-depression-in-adults-augmentation-of-antidepressants-with-stimulants-and-stimulant-like-drugs\" class=\"medical medical_review\">Unipolar major depression in adults: Augmentation of antidepressants with stimulants and stimulant-like drugs</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=unipolar-major-depression-in-adults-choosing-initial-treatment\" class=\"medical medical_review\">Unipolar major depression in adults: Choosing initial treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=unipolar-major-depression-in-adults-indications-for-and-efficacy-of-electroconvulsive-therapy-ect\" class=\"medical medical_review\">Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=unipolar-treatment-resistant-depression-in-adults-epidemiology-risk-factors-assessment-and-prognosis\" class=\"medical medical_review\">Unipolar treatment resistant depression in adults: Epidemiology, risk factors, assessment, and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=using-scales-to-monitor-symptoms-and-treat-depression-measurement-based-care\" class=\"medical medical_review\">Using scales to monitor symptoms and treat depression (measurement based care)</a></li></ul></div></div>","javascript":null}